Barclays PLC Has $1.49 Million Holdings in Fate Therapeutics, Inc. (NASDAQ:FATE)

Barclays PLC increased its stake in shares of Fate Therapeutics, Inc. (NASDAQ:FATE) by 245.3% in the third quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 424,277 shares of the biopharmaceutical company’s stock after purchasing an additional 301,389 shares during the period. Barclays PLC owned approximately 0.37% of Fate Therapeutics worth $1,485,000 as of its most recent SEC filing.

Other institutional investors have also made changes to their positions in the company. Dark Forest Capital Management LP acquired a new stake in shares of Fate Therapeutics during the second quarter worth $63,000. DRW Securities LLC acquired a new stake in shares of Fate Therapeutics during the second quarter worth $71,000. Castleview Partners LLC acquired a new stake in shares of Fate Therapeutics during the third quarter worth $73,000. Arizona State Retirement System acquired a new stake in shares of Fate Therapeutics during the second quarter worth $84,000. Finally, Headlands Technologies LLC lifted its holdings in Fate Therapeutics by 5,258.6% during the second quarter. Headlands Technologies LLC now owns 28,508 shares of the biopharmaceutical company’s stock worth $94,000 after acquiring an additional 27,976 shares in the last quarter. 97.54% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, Director Redmile Group, Llc bought 397,964 shares of the company’s stock in a transaction that occurred on Friday, December 20th. The shares were acquired at an average price of $1.68 per share, for a total transaction of $668,579.52. Following the completion of the acquisition, the director now owns 12,884,277 shares of the company’s stock, valued at approximately $21,645,585.36. The trade was a 3.19 % increase in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 5.00% of the company’s stock.

Analyst Ratings Changes

Several research analysts have weighed in on the company. Wedbush reiterated a “neutral” rating and set a $5.00 target price on shares of Fate Therapeutics in a report on Tuesday, November 12th. Needham & Company LLC reiterated a “hold” rating on shares of Fate Therapeutics in a report on Tuesday, November 19th. Finally, Bank of America upgraded Fate Therapeutics from an “underperform” rating to a “neutral” rating in a report on Monday, November 18th. One investment analyst has rated the stock with a sell rating, seven have given a hold rating and three have issued a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $6.75.

Fate Therapeutics Price Performance

Shares of Fate Therapeutics stock opened at $1.47 on Monday. The firm has a market cap of $167.42 million, a price-to-earnings ratio of -0.89 and a beta of 2.02. The stock’s 50-day moving average is $2.16 and its 200-day moving average is $3.11. Fate Therapeutics, Inc. has a one year low of $1.45 and a one year high of $8.83.

Fate Therapeutics (NASDAQ:FATE) last issued its quarterly earnings results on Tuesday, November 12th. The biopharmaceutical company reported ($0.40) EPS for the quarter, beating analysts’ consensus estimates of ($0.42) by $0.02. The company had revenue of $3.07 million for the quarter, compared to analyst estimates of $0.88 million. Fate Therapeutics had a negative return on equity of 45.88% and a negative net margin of 1,325.43%. On average, equities analysts expect that Fate Therapeutics, Inc. will post -1.72 EPS for the current year.

Fate Therapeutics Company Profile

Fate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders.